SynthesisReviews in endocrine & metabolic disorders2026
Association between metabolic dysfunction-associated steatotic liver disease/non-alcoholic fatty liver disease and chronic kidney disease: a systematic review and meta-analysis.
Synthesis in Reviews in endocrine & metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Data from current literature have suggested a positive association between Steatotic Liver Disease (SLD) and Chronic Kidney Disease (CKD). In 2023, a consensus of experts suggested that the term metabolic associated steatotic liver disease (MASLD) be used instead of non-alcoholic fatty liver disease (NAFLD), a term that had long been used to indicate the situation of hepatic steatosis not related to alcohol consumption or secondary to another etiology. The majority of hepatologists accepted this suggestion. To critically analyze this described association and compare the impact of change in criteria, we performed a systematic review followed by meta-analysis of incidence studies that evaluated the occurrence of new cases of CKD in patients diagnosed with NAFLD and MAFLD/MASLD. We searched the PubMed, LILACS, SciELO, and Cochrane Library databases for longitudinal studies published through June 2025 that included groups with NAFLD, MAFLD, and/or MASLD, as well as a control group, in the adult population without CKD at baseline. Among 2,099 studies found, twenty met the inclusion criteria. Compared to the patient's control group, the risk ratio (RR) for incidence of CKD in the group with MAFLD, MASLD, and NAFLD was 1.29 (1.18-1.40), 1.16 (1.12-1.19) and 1.25 (1.14-1.36), respectively. In a new analysis grouping MASLD with MAFLD to assess the impact of the terminology shift, the results remained similar. This review demonstrates that SLD is associated with the risk of developing CKD, regardless of classification. However, this connection needs further elucidation of its mechanisms to comprehend it better and prevent its impact.
Indexed as
Identifiers
42270864What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.